



# Atrial Fibrillation During an Exploration Class Mission

Mark Lipsett MD, PhD  
Douglas Hamilton MD, PhD  
Jay Lemery MD  
James Polk DO






# Disclosure Information

82nd Annual Scientific and Human Performance Meeting  
Mark Lipsett, Douglas Hamilton, Jay Lemery, James Polk

Have no financial relationships to disclose

The authors will not discuss off-label use and/or  
investigational use in this presentation




# Outline

- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources
- 5 Distant Medical Management
- 6 Mission Summary



# Outline


- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources
- 5 Distant Medical Management
- 6 Mission Summary



# Mission Background

1

- \* After a several month journey, the 7-member crew is preparing to enter a low Mars orbit
- \* You, the **flight surgeon**, have just received the mission commander's video message supplemented with the crew's biometrics & health status
- \* The message, delayed by the 20 min transmission lag, confirms the "return to duty" criteria for mission specialist (M.C.)




# Medical Background

- \* M.C., a 51-yo mission scientist had presented 2 months earlier via a “store & forward” PMC with the chief complaint of **Cardiac Palpitations**
- \* M.C. indicated feeling a strange “fluttering” & “pressure” in his chest during these bouts
- \* Three episodes, lasting ~3hr & terminating with bed rest, were diagnosed as **Paroxysmal Atrial Fibrillation (PAF)**

# Medical Background

1

- \* M.C.'s cardiac exam 30 days before mission take-off indicated:
  - ∅ CAD risk factors
  - ∅ cardiac  $Ca^{2+}$  score
  - ∅ significant ectopy during Holter




# Medical Background

- \* M.C.'s cardiac exam 30 days before mission take-off indicated:
  - ∅ CAD risk factors
  - ∅ cardiac  $Ca^{2+}$  score
  - ∅ significant ectopy during Holter
- \* EKG obtained during all three **PAF** episodes revealed
  - AF** with: ventricular rate of ~150 bpm
  - narrow complex QRS
  - ∅ ST- or T-wave abnormalities

# Medical Background

1


- \* M.C.'s cardiac exam 30 days before mission take-off indicated:  $\emptyset$  CAD risk factors  
 $\emptyset$  cardiac  $\text{Ca}^{2+}$  score



# Medical Background

1

- \* M.C.'s cardiac exam 30 days before mission take-off indicated:
  - ∅ CAD risk factors
  - ∅ cardiac  $Ca^{2+}$  score
  - ∅ significant ectopy during Holter
- \* EKG obtained during all three **PAF** episodes revealed **AF** with:
  - ventricular rate of ~150 bpm
  - narrow complex QRS
  - ∅ ST- or T-wave abnormalities
- \* M.C. indicated having an **URTI** 3 weeks before the first bout of **PAF** in which pseudo-ephedrine was used and a slight hand tremor was noted



# Medical Background AF & the Astronaut Corps

- \* Since 1950s, 17 cases of **AF** have been diagnosed amongst 317 active & retired astronauts (~5%)

# Medical Background AF & the Astronaut Corps

- \* Since 1950s, 17 cases of **AF** have been diagnosed amongst 317 active & retired astronauts (~5%)
- \* Since 2001, 5 astronauts underwent **RFA** treatment for atrial arrhythmias

# Medical Background AF & the Astronaut Corps

- \* Since 1950's 17 cases of **AF** have been diagnosed amongst 317 active & retired astronauts (~5%)
- \* Since the 2001, 5 astronauts underwent **RFA** treatment for atrial arrhythmias
- \* Of significance is the younger age (~40s) in which these arrhythmias are detected (vs >60 years)


# Medical Background

## AF & the Astronaut Corps

- \* Since 1950s, 17 cases of **AF** have been diagnosed amongst 317 active & retired astronauts (~5%)
- \* Since 2001, 5 astronauts underwent **RFA** treatment for atrial arrhythmias
- \* Of significance is the younger age (~40s) in which these arrhythmias are detected (vs >60 years)
- \* Due to: better health surveillance?  
higher vagal tone?  
random chance?  
gravitational-flux induced?


# Outline

- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources
- 5 Distant Medical Management
- 6 Mission Summary



# Outline


- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources
- 5 Distant Medical Management
- 6 Mission Summary



# Terrestrial Mechanisms of Atrial Fibrillation

2

- \* Structural Heart Disease
- \* Pericarditis
- \* Metabolic Disturbances
- \* Ectopic Beats
- \* Myocardial Stretch
- \* Idiopathic



# Mission Question 1: What Caused M.C.'s AF?


- a CO poisoning
- b Cardiomyopathy
- c Iatrogenic
- d Idiopathic AF (lone AF)
- e Myocardial infarction
- f Pericarditis
- g Post-viral thyrotoxicosis
- h Pulmonary embolism
- i Structural

# Mission Question 1: What Caused M.C.'s AF?

- a CO poisoning
- b Cardiomyopathy
- c Iatrogenic
- d Idiopathic AF (lone AF)**
- e Myocardial infarction
- f Pericarditis
- g Post-viral thyrotoxicosis
- h Pulmonary embolism
- i Structural


# Outline

- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources
- 5 Distant Medical Management
- 6 Mission Summary



# Outline


- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars**
- 4 Medical Resources
- 5 Distant Medical Management
- 6 Mission Summary



# Continuation of Mission

3

- \* The space vehicle is preparing to fire its engines to enter a parking orbit around Mars
- \* Any chance of returning to Earth in less than 1 year is impossible



# Mission Question 2:

## At this point you decide to...

- a continue mission, watchful waiting, **EKG** when symptomatic
- b Abort mission due to poor prognosis & risk of **thromboembolic event**
- c continue mission, start **ASA** daily with bi-monthly **EKG** follow-up exams
- d continue mission, start a  **$\beta$ -blocker** for possible thyrotoxic disease


# Mission Question 2:

## At this point you decide to...

- a continue mission, watchful waiting, **EKG** when symptomatic
- b Abort mission due to poor prognosis & risk of **thromboembolic event**
- c** continue mission, start **ASA** daily with bi-monthly **EKG** follow-up exams
- d continue mission, start a  **$\beta$ -blocker** for possible thyrotoxic disease


# Outline

- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources
- 5 Distant Medical Management
- 6 Mission Summary



# Outline


- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources**
- 5 Distant Medical Management
- 6 Mission Summary



# The Mission at Home

4


- \* The last few weeks have been a harrowing experience for you as the mission Flight Surgeon



# The Mission at Home

4


- \* The last few weeks have been a harrowing experience for you as the mission flight surgeon
- \* You have organized an international aerospace cardiology expert panel to decide:



# The Mission at Home

4


- \* The last few weeks have been a harrowing experience for you as the mission Flight Surgeon
- \* You have organized an international aerospace cardiology expert panel to decide:
  - abort mission, sling-shot burn around Mars and return to Earth within 6 months



# The Mission at Home

4

- \* The last few weeks have been a harrowing experience for you as the mission Flight Surgeon
- \* You have organized an international aerospace cardiology expert panel to decide:
  - abort mission, sling-shot burn around Mars and return to Earth within 6 months
  - continuing with the Mars landing and subsequent 1-year surface endeavour



# The Mission at Home

## Crew Supplies

- \* Adequate ASA for the whole mission



# The Mission at Home


## Crew Supplies

- \* Adequate ASA for the whole mission
- \* Insufficient anti-coagulation, rate control & rhythm control medications for one astronaut

# The Mission at Home

## Crew Supplies

- \* Adequate ASA for the whole mission
- \* Insufficient anti-coagulation, rate-control & rhythm control medications for one astronaut
- \* An Automatic External Defibrillator (AED) device



# Mission Question 3:

## Inquest

In your testimony to the international experts' conference, you state that:

- a ASA is just as effective as warfarin for anti-coagulation
- b the risks and difficulty monitoring warfarin therapy outweigh the stroke risk reduction
- c low-molecular weight heparin is not effective in treating thromboembolic risks associated with AF
- d Immediate electrical cardioversion would preclude the need for anticoagulation

# The Mission at Home

## Inquest

- \* At the experts' panel, you present an extensive pre-mission risk/benefit study analysis:
  - long-duration mission profile
  - age and excellent health of crew
  - risk of lone AF and subsequent crew member impact, including fatal stroke
- \* Conclusions:  
impact & risk of warfarin therapy > ASA therapy
- \* At time of mission planning, newer direct thrombin inhibitors not yet vetted

# Mission Question 3: Inquest

In your testimony to the international experts' conference, you state that:

- a ASA is just as effective as warfarin for anti-coagulation
- b the risks and difficulty monitoring warfarin therapy outweigh the stroke risk reduction
- c low-molecular weight heparin is not effective in treating thromboembolic risks associated with AF
- d Immediate electrical cardioversion would preclude the need for anticoagulation

# Mission Question 3:


## Inquest

In your testimony to the international experts' conference, you state that:

- a ASA is just as effective as warfarin for anti-coagulation
- b the risks and difficulty monitoring warfarin therapy outweigh the stroke risk reduction**
- c low-molecular weight heparin is not effective in treating thromboembolic risks associated with AF
- d Immediate electrical cardioversion would preclude the need for anticoagulation

# Outline

- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources
- 5 Distant Medical Management
- 6 Mission Summary



# Outline

- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources
- 5 Distant Medical Management**
- 6 Mission Summary



# Continuation of Mission

5

- \* Their Mars surface mission proceeded uneventfully until ~1 year after landing when M.C. noticed 24 hours of persistent palpitations, just 3 days before scheduled lift-off & return



# Continuation of Mission

5

\* Their Mars surface mission proceeded uneventfully until ~1 year after landing when M.C. noticed 24 hours of persistent palpitations, just 3 days before scheduled lift-off & return

\* Holter confirmed: **AF** - rapid ventricular response  
**165 bpm**  
pressure **90/50 mmHg**



# Continuation of Mission


5

- \* Their Mars surface mission proceeded uneventfully until ~1 year after landing when M.C. noticed 24 hours of persistent palpitations, just 3 days before scheduled lift-off & return
- \* Holter confirmed: **AF** - rapid ventricular response  
165 bpm  
pressure **90/50** mmHg
- \* M.C. notes feeling uncomfortable, but denies chest pressure or dyspnea

# Mission Question 4:

At this point, you would recommend:

- a **Nothing**, M.C. can be expected to spontaneously convert to NSR in the next 24 hours
- b **Rate control** and reassess
- c **Rate control** and initiate immediate **chemical cardioversion**
- d **Immediate electrical** cardioversion due to **hypotension**



# Mission Question 4:

At this point, you would recommend:

- a Nothing, M.C. can be expected to spontaneously convert to NSR in the next 24 hours
- b Rate control and reassess**
- c Rate control and initiate immediate chemical cardioversion
- d Immediate electrical cardioversion due to hypotension



# Mission Question 4:

- \* Rate control first choice, AF can ↓ ventricular filling by ~20%

# Mission Question 4:

- \* Rate control first choice, AF can ↓ ventricular filling by ~20%
- \*  $\text{Ca}^{2+}$  channel blocker vs  $\beta$ -blocker, side-effects

# Mission Question 4:


- \* Rate control first choice, AF can ↓ ventricular filling by ~20%
- \* Ca<sup>2+</sup> channel blocker vs β-blocker, side-effects
- \* Spontaneous conversion common <24 hours (~67%)

# Mission Question 4:

- \* Rate control first choice, AF can ↓ ventricular filling by ~20%
- \* Ca<sup>2+</sup> channel blocker vs β-blocker, side-effects
- \* Spontaneous conversion common <24 hours (~67%)
- \* Electrical cardioversion only when symptomatic

# Outline

- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources
- 5 Distant Medical Management
- 6 Mission Summary



# Outline


- 1 Background
- 2 Causes of Atrial Fibrillation
- 3 Mission to Mars
- 4 Medical Resources
- 5 Distant Medical Management
- 6 **Mission Summary**



# Continuation of Mission

6

- \* Crew member M.C. continued to take ASA and was acutely rate controlled with  $\text{Ca}^{2+}$  CB



# Continuation of Mission

6


- \* Crew member M.C. continued to take ASA and was acutely rate controlled with  $\text{Ca}^{2+}$  CB
- \* Of interest was his conversion back to NSR during the 4 minutes of  $3G_x$  loading during lift off from the Martian surface




# Continuation of Mission

6

- \* Crew member M.C. continued to take ASA and was acutely rate controlled with  $\text{Ca}^{2+}$  CB
- \* Of interest was his conversion back to NSR during the 4 minutes of  $3G_x$  loading during lift off from the Martian surface
- \* M.C. remained in NSR for the duration of the journey back to Earth and the mission was completed successfully




# Summary



This case was to acquaint the audience with the tremendous challenges that face the flight surgeon and medical team when supporting a space mission



# Summary



- \* This case was to acquaint the audience with the tremendous challenges that face the FS and medical team when supporting a space mission
- \* Limited crew training time, medical hardware & pharmaceuticals manifested dictate aggressive 1<sup>o</sup> & 2<sup>o</sup> prevention strategies to protect a multi-billion dollar asset like the ISS or a mission to the Moon or Mars



# Acknowledgements

- Dept. Anaesthesia  
Memorial University
- Wyle Life Sciences
- NASA - JSC
- CSA
- Jillian Pashley

